Skip to content

Kodiak Sciences Inc KOD Other Commercial Liabilities

Other Commercial Liabilities at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
Vera Therapeutics logo
Vera TherapeuticsVERA
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's other commercial liabilities?
Kodiak Sciences Inc (KOD) reported other commercial liabilities of $26.57M in Q1 2026.
How has Kodiak Sciences Inc's other commercial liabilities changed year-over-year?
Kodiak Sciences Inc's other commercial liabilities increased by 98.5% year-over-year, from $13.39M to $26.57M.
What is the long-term trend for Kodiak Sciences Inc's other commercial liabilities?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's other commercial liabilities has grown at a 0.2% compound annual growth rate (CAGR), from $20.4M to $20.61M.